Aims: Paired-like homeobox 2b (PHOX2B) is a transcription factor with expression outside of the central nervous system restricted to neurons and chromaffin cells of the autonomic nervous system. Germline mutations cause congenital central hypoventilation syndrome and predispose to neuroblastoma and Hirschsprung disease. Among paediatric small round cell tumours, PHOX2B is neuroblastoma-specific. Two studies of adult autonomic nervous system tumours (n = 62) produced conflicting results (all tumours stained in one; expression restricted to 40% of paragangliomas in the other). We examined PHOX2B expression in a large cohort of phaeochromocytomas and paragangliomas, as well as well-differentiated neuroendocrine tumours (WDNETs) and poorly differentiated neuroendocrine carcinomas (PDNECs). Methods and results: Tissue microarrays (TMAs) were constructed from 609 tumours: 111 phaeochromocytomas, 146 paragangliomas, 250 WDNETs, and 102 PDNECs. PHOX2B immunohistochemistry was scored for extent (%) and intensity (0-3+), and an H-score (extent 9 intensity) was calculated. PHOX2B expression was seen in 32% of phaeochromocytomas and in 47% of paragangliomas. Mean/median H-scores for these tumours were in the 30-55 range (i.e. weak to moderate staining). No WDNETs and only 7% of PDNECs stained, the latter often strongly. In a representative cohort of corresponding whole sections (n = 55), the results in WDNETs and PDNECs were unchanged, whereas half of the phaeochromocytomas/paragangliomas that were negative on TMAs became focally, weakly positive. Conclusions: We found frequent, weak to moderate PHOX2B expression in phaeochromocytomas/paragangliomas and no expression in WDNETs, which could be diagnostically useful in the distinction of these tumours. Expression in a minority of PDNECs probably reflects the transcription factor lineage infidelity that is characteristic of this tumour class.
Introduction
The transcription factor paired-like homeobox 2b (PHOX2B) has been referred to as the master regulator of the autonomic nervous system and of the noradrenergic phenotype. Among neural crest derivatives, PHOX2B is expressed by: sympathetic, parasympathetic and enteric ganglia; adrenal and extra-adrenal chromaffin cells; and glomus cells. [1] [2] [3] [4] [5] In the Phox2b homozygous knockout mouse, sympathetic and parasympathetic ganglia degenerate; enteric ganglia undergo migration arrest in the foregut and subsequently degenerate; and, although the adrenal medulla forms, tyrosine hydroxylase and dopamine-bhydroxylase (key enzymes in the synthesis of noradrenaline) are not expressed. 2 Germline PHOX2B mutations cause congenital central hypoventilation syndrome, 3, 6, 7 and predispose to neuroblastoma 3, [7] [8] [9] [10] [11] and Hirschsprung disease. 3, 7, 8, 10 Neuroblastoma is a primitive tumour of sympathoadrenal lineage. Given PHOX2B's central role in determining this lineage, it is not surprising that it has been investigated as a diagnostic marker of neuroblastoma, in which it has been shown to be highly sensitive and specific as an immunohistochemical marker, including in decalcified bone marrow specimens, [12] [13] [14] and in quantitative real-time polymerase chain reaction panels as a marker of minimal residual disease. [15] [16] [17] PHOX2B has been similarly investigated as a marker of the neuroendocrine autonomic nervous system tumours, namely phaeochromocytoma and paraganglioma, with conflicting results in two studies. Whereas one group found PHOX2B expression in six of six such tumours, 12 another found expression in 40% of 35 paragangliomas and in none of 21 phaeochromocytomas. 13 We sought to examine PHOX2B expression in a large cohort of phaeochromocytomas and paragangliomas, as well as in welldifferentiated neuroendocrine tumours (WDNETs) and poorly differentiated neuroendocrine carcinomas (PDNECs), which represent key differential diagnostic considerations, owing to substantial morphological and immunophenotypic overlap. PHOX2B immunohistochemistry was performed manually on 4-lm-thick tissue sections after deparaffinization, rehydration, and pressure cooker heatinduced epitope retrieval in Target Retrieval Solution (pH 6.1; Dako; Carpinteria, CA, USA) with a rabbit monoclonal antibody (clone EPR14423; 1:500 dilution; Abcam, Cambridge, MA, USA) and the polymer-based Dako EnVision+ detection system. A neuroblastoma served as the positive control, and a multi-tissue block including normal skin, skeletal muscle and colon served as the negative control. PHOX2B expression was evaluated for extent (0-100%) and intensity (0-3+) in each TMA core, and an overall H-score (mean extent 9 intensity) was calculated for each tumour, with any non-zero H-score considered to be positive.
Materials and methods

Phaeochromocytomas
The results of PHOX2B staining in phaeochromocytomas and paragangliomas in TMAs were correlated with the results of previously performed succinate dehydrogenase B (SDHB) immunohistochemistry. 22 SDHB immunohistochemistry was performed similarly to that for PHOX2B, with a mouse monoclonal antibody (clone 21A11AE7; 1:100; Abcam). Staining was assessed as intact (any cytoplasmic staining) or lost (entirely absent in tumour with intact internal control).
The results of PHOX2B staining in the TMAs were validated in a representative cohort of corresponding whole sections, including cases with null (H-score = 0), low (H-score < 100) and high (H-score ≥ 100) expression on TMAs. This cohort included 10 WDNETs (all null), 15 PDNECs (eight null, three low, and two high), 15 phaeochromocytomas (five null, five low, and five high), and 15 paragangliomas (five null, five low, and five high). Whole section PHOX2B immunohistochemistry was again scored for extent (0-100%) and intensity (0-3+) of staining, and an H-score was calculated.
Two-sided Fisher's exact and Kruskal-Wallis tests were used to analyse categorical and continuous data, respectively. Linear regression was used to describe the relationship between PHOX2B results in TMAs and whole sections. A P-value of <0.05 was considered to be significant. This research was conducted with University of Iowa Institutional Review Board approval.
Results
P H O X 2 B E X P R E S S I O N I N T M A S
PHOX2B expression was seen in 32% (35/111) of phaeochromocytomas and in 47% (69/146) of paragangliomas (P = 0.015), including 52% of head and neck tumours and 32% of thoracoabdominal tumours (P = 0.052). Mean and median H-scores for these tumour types were in the 30-55 range (P = 0.798), corresponding to weak to moderate staining (Figure 1A,D) . No WDNETs (0/250) and only 7% (7/102; one lung, three extrapulmonary visceral, and three Merkel cell) of PDNECs expressed PHOX2B, the latter tumour type often strongly (mean and median Hscores in positives of 140 and 210) ( Figure 1B,C,E,F) . Moderate to strong PHOX2B expression was also noted in enteric ganglion cells and was not seen in enteroendocrine cells of the ileum or in islets of Langerhans (Figure 2A,B) . Expression data are summarized in Table 1 .
C O R R E L A T I O N O F P H O X 2 B T M A R E S U L T S W I T H S D H B R E S U L T S
There was no relationship between PHOX2B positivity and succinate dehydrogenase (SDH) status (P = 0.68 for phaeochromocytomas, P = 0.64 for paragangliomas, and P = 0.31 for all phaeochromocytomas and paragangliomas). SDH deficiency, defined by loss of SDHB expression, was seen in 6% of phaeochromocytomas and in 14% of paragangliomas. 
R E L A T I O N S H I P B E T W E E N P H O X 2 B E X P R E S S I O N I N T M A A N D I N C O R R E S P O N D I N G W H O L E S E C T I O N S
PHOX2B expression in TMAs and that in corresponding whole sections were significantly related (r 2 = 0.81; P < 0.0001; Figure 3 ). Considering the categories of null, low and high PHOX2B expression, eight of 55 (15%) tumours' PHOX2B status was reclassified in corresponding whole sections; seven were upgraded and one was downgraded, all of only one class (that is, no tumour went from null to high and vice versa). All 10 WDNETs remained negative on whole sections, and only one of 15 (7%) PDNECs was reclassified (H-score = 33 on TMA to H-score = 180 on whole section). Seven of 30 (23%) phaeochromocytomas/paragangliomas were reclassified, with five of 10 going from null to low (with whole section H-scores of 2, 2, 5, 5 and 20, corresponding to 'rare cells, weak' staining); in addition, one tumour each went from low to high (H-score = 30 to H-score = 160) and high to low (H-score = 140 to H-score = 80). On whole sections of phaeochromocytoma, weak to moderate staining of non-neoplastic adrenal medulla was observed ( Figure 2C ).
Discussion
Using a rabbit monoclonal antibody, we detected PHOX2B expression in a significant fraction of phaeochromocytomas and paragangliomas, no expression in WDNETs, and infrequent expression in PDNECs. In TMAs, the overall rate of positivity in phaeochromocytomas and paragangliomas was 40%; this rate probably reflects the frequency of positivity in small biopsies of these tumours. In a representative set of corresponding whole sections, PHOX2B results for WDNETs and PDNECs were essentially unchanged. Among a subset of 10 phaeochromocytomas/paragangliomas that were null on TMAs, five were upgraded to low (i.e. rare cells, weak) on corresponding whole sections. On the assumption that this finding is representative (i.e. that half of TMA-null cases are in fact low-positive), the estimated rate of PHOX2B positivity in whole sections of resection specimens is 70%. This discrepancy between TMA and whole section positivity is not entirely surprising, given the generally weak to moderate staining seen in these two tumour types (and in non-neoplastic adrenal medulla). Bielle et al. initially reported PHOX2B expression in 100% of a limited number of phaeochromocytomas (n = 4), a paraganglioma (n = 1), sympathetic ganglia neurons (n = 2), enteric nervous system neurons (n = 1), and adrenal medulla chromaffin cells (n = 6). 12 Staining in these tumours was noted to be weaker than in neuroblastomas and ganglioneuroblastomas, and staining in the normal anatomical tissues/structures was noted to be weak. The authors utilized a goat polyclonal antibody (H-20). Nonaka et al., utilizing the same goat polyclonal antibody, subsequently reported expression in 40% of 35 paragangliomas, noting expression to be variable and generally weak, and in no phaeochromocytomas (n = 21); ganglion cells and chromaffin cells were also negative. 13 Regarding neuroendocrine autonomic nervous system tumours, we attribute the discrepancy in these studies to a 'small numbers bias' in the Bielle and Nonaka studies and a relatively insensitive assay in the Nonaka study, given the lack of staining in the normal tissues/structures expected to express PHOX2B. Regarding the discrepancy in the frequency of positivity in paragangliomas (40%) and phaeochromocytomas (0%) in the Nonaka study, it is of note that, whereas 10 of 35 (29%) paragangliomas were examined in whole sections (and the remainder in TMAs), only three of 21 (14%) phaeochromocytomas were.
A genome-wide association study identified PHOX2B as a Crohn's disease susceptibility locus. 23 In this same study, normal mouse ileum and human colon samples were immunostained for PHOX2B, with the authors reporting staining in a 'subset of epithelial cells, possibly neuroendocrine cells'; the antibody source was not specified. It is of note that multiple subsequent genome-wide association studies failed to replicate the significance of PHOX2B as a Crohn's susceptibility locus. [24] [25] [26] [27] Moran et al., examining the significance of enteroendocrine cells in ileal Crohn's disease, reported PHOX2B colocalization with glucagon-like peptide-1 and chromogranin A in a subset (~15%) of ileal enteroendocrine cells. 28 These findings, in addition to differential diagnostic considerations, led us to include WDNETs in our study cohort. We found no PHOX2B expression in 250 WDNETs or in any ileal enteroendocrine cells or islets of Langerhans. Similarly, Nonaka et al. found no PHOX2B expression in 89 WDNETs. 13 It is of note that the Moran study utilized a rabbit polyclonal PHOX2B antibody and avidin-biotin-based detection chemistry, both of which could have contributed to a non-specific result.
We detected PHOX2B expression in a fraction (7%) of PDNECs, including 3% of lung, 14% of extrapulmonary visceral and 7% of cutaneous neoplasms. We attribute this expression to the 'transcription factor lineage infidelity' that is characteristic of this class of tumours (i.e. PDNECs tend to express multiple transcription factors, irrespective of their site of origin). 29 Nonaka et al. had previously failed to demonstrate PHOX2B expression in 50 PDNECs. 13 Diffuse, strong PHOX2B expression would favour a diagnosis of PDNEC over phaeochromocytoma/paraganglioma. Four of seven (57%) PHOX2B-positive PDNECs were high expressors, all with H-scores of >200, whereas only 13% and 4% of PHOX2B-positive phaeochromocytomas/paragangliomas had H-scores of ≥100 and ≥200, respectively.
Phaeochromocytomas, paragangliomas, WDNETs and PDNECs are all neuroendocrine neoplasms, characterized by the expression of general neuroendocrine markers (i.e. chromogranin A and/or synaptophysin) and the production of peptide hormones and/or biogenic amines. WDNETs and PDNECs are generally distinguished from the former on the basis of their epithelial nature (i.e. they express keratins), though keratin expression may be patchy; 30, 31 although phaeochromocytomas and paragangliomas classically do not express keratins, 32, 33 there is a rare report to the contrary. 34 Phaeochromocytomas and paragangliomas classically contain sustentacular cells, 35, 36 although WDNETs often do, too; 31, 37, 38 this is an underrecognized fact that we have seen lead to diagnostic errors. In the setting of a neuroendocrine neoplasm, PHOX2B expression, although relatively insensitive, would support a diagnosis of phaeochromocytoma/paraganglioma over a diagnosis of WDNET or PDNEC.
Other markers that we have previously employed in this differential include SDHB 39, 40 and GATA-3.
13,41,42 SDH is inactivated in 5-10% of phaeochromocytomas and in 15% and 30% of paragangliomas of head and neck and thoracoabdominal origin, respectively, which leads to loss of expression of SDHB. The multispecific transcription factor GATA-3 has been found to be expressed by the vast majority of phaeochromocytomas (93%; 42/45) and paragangliomas (83%; 86/104) in three studies, 13, 41, 42 and not by WDNETs (0/133) or PDNECs (0/84). 13, 42 It is of note that expression of the pancreatic WDNET marker Islet 1 was also seen in six of six paragangliomas/ phaeochromocytomas in one study. 43 Given these latter findings, it should not be surprising that, like PHOX2B, both GATA-3 [44] [45] [46] [47] and Islet 1 48 are critical to sympathoadrenal development. Immunohistochemical markers that are potentially useful in the differential diagnosis of phaeochromocytoma/paraganglioma, WDNET and PDNEC are summarized in Table 2 .
Conclusions
PHOX2B, the master regulator of the autonomic nervous system and of the noradrenergic phenotype, is expressed by a significant fraction of phaeochromocytomas and paragangliomas and is not expressed by WDNETs. In laboratories employing PHOX2B as a neuroblastoma marker, expression may also be used to support a diagnosis of phaeochromocytoma/paraganglioma over that of WDNET/PDNEC. Whereas staining in neuroblastomas is typically diffuse and strong, the staining in phaeochromocytomas and paragangliomas is more likely to be of weak to moderate intensity and of more limited extent, such that the estimated rate of positivity in small biopsy material (40%) is lower than that in whole sections of resected tumours (70%). Otherwise, among low-grade to intermediate-grade neuroendocrine neoplasms, the single best marker to support a diagnosis of phaeochromocytoma/paraganglioma would appear to be GATA-3, whereas broad-spectrum keratin expression would support a diagnosis of WDNET. Rare PHOX2B expression, which is often strong, in PDNECs may be a manifestation of the 'transcription factor lineage infidelity' that is typical of this class of tumours.
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